JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

Search

Xenon Pharmaceuticals Inc

Fermé

SecteurSoins de santé

30.38 -2.03

Résumé

Variation du prix de l'action

24h

Actuel

Min

30.21

Max

30.69

Chiffres clés

By Trading Economics

Revenu

638K

-65M

Ventes

7.5M

7.5M

Marge bénéficiaire

-867.293

Employés

316

EBITDA

4.1M

-73M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+83.63% upside

Dividendes

By Dow Jones

Prochains Résultats

7 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-330M

2.4B

Ouverture précédente

32.41

Clôture précédente

30.38

Sentiment de l'Actualité

By Acuity

75%

25%

339 / 375 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

Xenon Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

25 juil. 2025, 17:53 UTC

Principaux Mouvements du Marché

Genworth Shares Rise On UK Court Ruling That Could Lead to $750 Million Windfall

25 juil. 2025, 15:58 UTC

Résultats
Principaux Mouvements du Marché

Aon Shares Rise After 2Q Earnings Beat

25 juil. 2025, 15:08 UTC

Principaux Mouvements du Marché

AST SpaceMobile Shares Slide After Convertible Notes, Stock Offerings

25 juil. 2025, 21:40 UTC

Market Talk

Starbucks' Spending Hikes Are Misdirected -- Market Talk

25 juil. 2025, 21:23 UTC

Market Talk

Honeywell's Growth Seen Holding Up Despite Recent Headwinds -- Market Talk

25 juil. 2025, 20:40 UTC

Résultats

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

25 juil. 2025, 20:10 UTC

Résultats

These Stocks Moved the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25 juil. 2025, 19:56 UTC

Résultats

Correction to Why Bargain Hunters Are Flocking to 'Bin Stores' -- Barrons.com on July 20

25 juil. 2025, 19:14 UTC

Market Talk

Oil Futures Post Back-to-Back Weekly Losses -- Market Talk

25 juil. 2025, 19:10 UTC

Market Talk

U.S. Natural Gas Futures Appear to Stabilize -- Market Talk

25 juil. 2025, 19:01 UTC

Résultats

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25 juil. 2025, 18:45 UTC

Market Talk

Gold Ends Down Week on Lower Note -- Market Talk

25 juil. 2025, 18:35 UTC

Acquisitions, Fusions, Rachats

Sale Could Fetch Around $1B, Sources Say -- WSJ

25 juil. 2025, 18:35 UTC

Acquisitions, Fusions, Rachats

LVMH in Talks to Sell Marc Jacobs -- WSJ

25 juil. 2025, 18:35 UTC

Acquisitions, Fusions, Rachats

Suitors for Marc Jacobs Include Authentic, Bluestar Alliance and WHP Global, Sources Say -- WSJ

25 juil. 2025, 18:35 UTC

Acquisitions, Fusions, Rachats

LVMH Exploring Sale of Fashion Brand Marc Jacobs, Sources Say -- WSJ

25 juil. 2025, 17:38 UTC

Principaux Mouvements du Marché

Genworth Shares Rise On UK Court Ruling That Could Lead to $750M Windfall

25 juil. 2025, 17:26 UTC

Market Talk

U.S. Oil Rig Count Extends Decline -- Market Talk

25 juil. 2025, 17:13 UTC

Résultats

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

25 juil. 2025, 16:46 UTC

Résultats

Volkswagen Teases Made-in-America Audis, Porsches After $1.5 Billion Tariff Hit -- 2nd Update

25 juil. 2025, 16:45 UTC

Résultats

Apple Earnings Are Next Week. Why This Analyst Says Be Cautious. -- Barrons.com

25 juil. 2025, 16:27 UTC

Résultats

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25 juil. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

25 juil. 2025, 16:02 UTC

Résultats
Acquisitions, Fusions, Rachats

Berkshire Stock Is Losing Its Buffett Premium. Now Is the Time to Buy. -- Barrons.com

25 juil. 2025, 15:34 UTC

Résultats

Intel's Harsh Reality Nullifies Tariff Boost -- WSJ

25 juil. 2025, 15:06 UTC

Market Talk

Base Metal Prices Fall on Stronger U.S. Dollar -- Market Talk

25 juil. 2025, 15:05 UTC

Résultats

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Comfort Systems, and More -- Barrons.com

25 juil. 2025, 14:45 UTC

Market Talk

Oil Rangebound Amid U.S.-EU Trade Uncertainty -- Market Talk

25 juil. 2025, 14:44 UTC

Market Talk

Gold Futures Set to End Week Lower on Easing Trade War Concerns -- Market Talk

25 juil. 2025, 14:36 UTC

Market Talk
Résultats

Phillips 66 CEO Says California Administration Supports of LA Plant Closure -- Market Talk

Comparaison

Variation de prix

Xenon Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

83.63% hausse

Prévisions sur 12 Mois

Moyen 55.64 USD  83.63%

Haut 65 USD

Bas 47 USD

Basé sur 14 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

14 ratings

14

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

34.81 / 38.24Support & Résistance

Court Terme

Strong Bearish Evidence

Moyen Terme

Bullish Evidence

Long Terme

Neutral Evidence

Sentiment

By Acuity

339 / 375Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.